**Abstract**

**Objective:** Cholinergic neurons in the nucleus accumbens (NAc) express δ and μ receptors that are thought to inhibit neural activity (Britt & McGehee, 2008). δ and μ receptors are divided into δ~1~ and δ~2~ receptors and μ~1~ and μ~2~ receptors, respectively. Therefore, we analysed the roles of δ and μ receptor subtypes in regulating accumbal acetylcholine (ACh) efflux using *in vivo* microdialysis.

**Methods:** Male Sprague-Dawley rats were used. ACh levels in accumbal perfusates, taken every 15 min, were determined by HPLC-ECD. Apart from the μ~1~ receptor antagonist naloxonazine, which was given intraperitoneally, δ and μ receptor ligands were administered intracerebrally through the dialysis probe. Doses of these compounds indicate total amount (mol) over a 30-min infusion time. To monitor basal ACh levels, a low concentration of physostigmine (50 nM) was added to the perfusate.

**Results**: The δ~1~ receptor agonist DPDPE (3 and 300 pmol) and δ~2~ receptor agonist deltorphin II (3 and 30 pmol) decreased accumbal ACh in a dose-related manner. DPDPE (300 pmol)- and deltorphin II (3 pmol)-induced reduction in ACh were each inhibited by co-administration of the δ~1~ receptor antagonist BNTX (0.3 pmol) and δ~2~ receptor antagonist NTB (15 pmol), respectively. The μ receptor agonists endomorphin (EM)-1 and EM-2 (6 and 30 nmol) decreased ACh in a dose-related manner. EM-1- and EM-2 (30 nmol)-induced reductions in ACh were prevented by co-administration of the μ receptor antagonist CTOP (3 nmol), which failed to alter basal ACh. Naloxonazine (15 mg/kg ip), which inhibits EM-1 (15 nmol)-induced accumbal dopamine efflux (Okutsu et al, 2006), did not alter EM-1 (30 nmol)- or EM-2 (30 nmol)-induced reductions in ACh.

**Conclusion:** This study provides *in vivo* evidence for δ~1~, δ~2~ and μ~2~ receptors, but not μ~1~ receptors, that are located on accumbal cholinergic neurons and inhibit accumbal ACh efflux.
